“Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Auto

To order this detailed 500+ page report, please visit this https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

Key Inclusions

A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromal cells and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. In addition, information on the various technology platforms being actively used for the development of stem cell therapies has been provided.

Identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas).

The report includes detailed transcripts of discussions held with the following experts:

William L Rust (Founder and Chief Executive Officer, Seraxis)

Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)

Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)

Kikuo Yasui (Director and Chief Operating Officer, Heartseed)

Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)

Gilles Devillers (President, Bio Elpida)

Fiona Bellot (Business Development Manager, Roslin Cell Therapies)

David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)

Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

To request sample pages, please visit this https://www.rootsanalysis.com/reports/296/request-sample.html